Teva Targets $4 Billion Lupus Market With Laquinimod Study

Teva Targets $4 Billion Lupus Market With Laquinimod Study

Adam Reynolds/Bloomberg

Teva plans to start a larger study soon, according to a spokesman for the Petach Tikva, Israel-based company.